Anchor Therapeutics Inc.
Frederick Jones, Cambridge, MA, US
Anchor Therapeutics is developing Pepducin™ lipopeptides, novel molecules that exquisitely target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signalling. Anchor has programs in oncology, inflammation, cardiovascular and GI disease.
Dr. Lauren Silverman (Board Seat)